Personalized ATG with or without verapamil for new type 1 diabetes
Treatments studied
Part of Hormones & metabolism, Immune system & allergy clinical trials.
This trial tests a new way to give a medicine called anti-thymocyte globulin (ATG) with or without verapamil, a blood pressure drug. It aims to slow down the loss of insulin-making cells in people newly diagnosed with type 1 diabetes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 6 and 35 years old.
- You must have been diagnosed with type 1 diabetes in the last 100 days.
- Your body must still make some insulin (a test called C-peptide measures this).
- You must be willing to get a flu shot if it's flu season, and avoid live vaccines during the study.
- You must not have a weak immune system, active infections, or certain medical conditions like heart disease or blood disorders.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a low dose of a drug that calms the immune system, followed by either another immune drug or a blood pressure medicine, to see if they can help preserve the body's ability to make insulin in people recently diagnosed with type 1 diabetes. It may help keep your own insulin production going longer.
This study tests if verapamil (a common blood pressure medication) can help children newly diagnosed with type 1 diabetes keep making their own insulin for longer. It aims to preserve the body's own insulin-producing cells, which may reduce the amount of insulin injections needed.
This trial tests an investigational drug that may help preserve the body's ability to make insulin in people with type 1 diabetes. It aims to slow the progression of the disease and reduce the need for insulin injections.
This Phase 2 study tests whether starting with cyclosporine and then giving low-dose IL-2 can better protect the body’s insulin-producing function after type 1 diabetes is diagnosed. It’s meant for people diagnosed very recently who have specific diabetes-related immune markers.
This study compares two medicines (teplizumab and anti-thymocyte globulin) to see if they can delay the onset of type 1 diabetes in people who are at high risk but don't have symptoms yet. If you have certain diabetes-related antibodies in your blood, this trial might help keep full-blown diabetes away for longer.
This trial tests a medicine called anti-thymocyte globulin (h-ATG) to see if it can help people with type 1 diabetes keep making some of their own insulin. It may slow the loss of insulin-making cells and help manage blood sugar.
Hear when a new Type 1 diabetes trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.